DESTINY-Breast03 Phase 3 Study Results
100
90
90
Prevalence
80
Prevalence of Nausea and Vomiting
70
60
50
40
30
20
10
0
Nausea
Cycle
DESTINY-Breast03
100
Vomiting
90.
80
70
60
60
50
50
40.
40
30
20
10
123
Cycle
Daiichi-Sankyo
T-DXd (n=257)
T-DM1 (n=261)
T-DXD 257 256 254 252 247 242 227 225 215 213 203 197 191 182 175 172 167 160 153 149 138 136 126 117 105 97 85 76 62 50 44 40 31 27 22 19 17 17 10 8 6 5 21 T-DXd 257 256 254 252 247 242 227 225 215 213 203 197 191 182 175 172 167 160 153 149 138 136 126 117 105 97 85 76 62 50 44 40 31 27 22 19 17 17 10 8 6 5 21
T-DM1 261 252 221 209 189 175 161 150 138 133 118 108 93 87 78 73 68 63 59 58 52 51 48 43 41 39 36 30 22 18 16 13 11 6 5 5 4 3 3 2 2 0 0 0 T-DM1 261 252 221 209 189 175 161 150 138 133 118 108 93 87 78 73 68 63 59 58 52 51 48 43 41 39 36 30 22 18 16 13 11 65 5 4 3 3 2 2 000
The prevalence of nausea and vomiting was higher with T-DXd than with T-DM1 and was relatively consistent over time
Majority of events with T-DXd were grade 1 and 2 and resolved, and one patient discontinued study drug due to vomiting
Antiemetic prophylaxis recommendations were updated during the study based on emerging data supporting the moderately emetogenic potential of
T-DXd1,2
T-DM1, trastuzumab emtansine; T-DXd, trastuzumab deruxtecan.
Prevalence was defined as the number of patients who had the event starting at a particular cycle or still ongoing at that cycle divided by the number of patients on treatment at that cycle.
1. Hesketh PJ et al. J Clin Oncol. 2020;38(24):2782-2797. 2. Modi S et al. N Engl J Med. 2020;382:610-621.
Safety update: Sept 7, 2021
ASCO 2022 #1000 Oral
32View entire presentation